Moderna Inc
MRNA: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| B<d | LOCK|@Y< | LOCK|>H%Yzjf |
Moderna Earnings: All Eyes on Upcoming Data for Oncology Therapy Intismeran
Moderna reported $389 million in revenue in the first quarter, but research and development spending and a $900 million legal settlement drove a $1.3 billion net loss. Moderna maintained guidance for up to 10% revenue growth in 2026. Shares fell 3% intraday on May 1.
